



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/1 U.S. PATENT & TRADEMARK OFFICE				Complete if Known	
				Application Number	09/802,686
				Filing Date	March 9, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1648
				Examiner Name	T. Brown
Sheet	1	of	2	Attorney Docket Number	
377882000900					

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
ll	1.	US-2002/0028784-A1	03-07-2002	Nest	
	2.	US-2002/0098199-A1	07-25-2002	Van Nest et al.	
	3.	US-2002/0107212-A1	08-08-2002	Nest et al.	
	4.	US-2003/0050263-A1	03-13-2003	Krieg et al.	
	5.	US-2003/0216340-A1	11-20-2003	Van Nest et al.	
	6.	US-2004/0009942-A1	01-15-2004	Van Nest	
	7.	US-2004/0030118-A1	02-12-2004	Wagner et al.	
	8.	US-2005/0059626-A1	03-17-2005	Van Nest et al.	
	9.	US-6,514,948-B1	02-04-2003	Raz et al.	
	10.	US-6,534,062-B2	03-18-2003	Raz et al.	
	11.	US-6,552,006-B2	04-22-2003	Raz et al.	
	12.	US-6,613,751-B2	09-02-2003	Raz et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number-Kind Code <sup>4</sup> (if known)			
ll	13.	WO-98/40100-A1	09-17-1998	Ottawa Civic Loeb Research Institute et al.	
ll	14.	WO-01/68116-A2,A3	09-20-2001	Dynavax Technologies Corporation	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
ll	15.	Baumann, N.M. et al. (December 1996). "Recurrent Respiratory Papillomatosis," <i>Pediatric Otolaryngology</i> 43(6):1385-1400.			
ll	16.	Beutner, K.R. et al. (February 1998). "Treatment of Genital Warts with an Immune-response Modifier (Imiquimod)," <i>Journal of the American Academy of Dermatology</i> 38(2, part 1):230-239.			
ll	17.	Clements, J.D. (1997). "Surface Warfare Against Pathogens Using Mucosal Vaccines," <i>Nature Biotech.</i> 15:622-623.			
ll	18.	Current Drugs Ltd. (February 24, 2003). "Lilly and 3M Suspend Resiquimod Trials," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Ref...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Ref...</a> >, last visited on October 13, 2005, 1 page.			
ll	19.	Current Drugs Ltd. (February 24, 2003). "Preliminary Data From Recently Completed Clinical Trials of Resiquimod Suggest Dosing Used in Studies will not Achieve Adequate Efficacy," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Ref...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Ref...</a> >, last visited on October 13, 2005, 1 page.			

Examiner Signature	<i>Cheryl L</i>	Date Considered	<i>6/05/06</i>
pa- 105164T			

considered  
Do not print



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/802,686
				Filing Date	March 9, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1648
				Examiner Name	T. Brown
Sheet	2	of	2	Attorney Docket Number	377882000900

20.	Guerrero-Plata, A. et al. (August 2005). "Activity and Regulation of Alpha Interferon in Respiratory Syncytial Virus and Human Metapneumovirus Experimental Infections," <i>Journal of Virology</i> 79(16):10190-10199.	<i>Considered</i>
21.	Hartmann, G. et al. (2000). "Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells," <i>J. Immunology</i> 164:944-952.	<i>Considered</i>
22.	Hartmann, G. et al. (February 1, 2000). "Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses in Vitro and In Vivo," <i>J. Immunol.</i> 164(3):1617-1624.	<i>Considered</i>
23.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07839 filed March 12, 2001, 4 pages.	<i>Considered</i>
24.	International Search Report mailed June 18, 2002 for PCT Application No. PCT/US01/07841 filed March 12, 2001, 6 pages.	<i>Considered</i>
25.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07931 filed March 12, 2001, 7 pages.	<i>Considered</i>
26.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07842 filed March 12, 2001, 6 pages.	<i>Considered</i>
27.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07840 filed March 12, 2001, 6 pages.	<i>Considered</i>
28.	Krieg, A.M. (August 1996). "An Innate Immune Defense Mechanism Based on the Recognition of CpG Motifs in Microbial DNA," <i>J. Lab. Clin. Med.</i> 128(2):128-133.	<i>Considered</i>
29.	Krieg, A.M. (2000). "The Role of CpG Motifs in Innate Immunity," <i>Current Opinion In Immunology</i> 12:35-43.	<i>Considered</i>
30.	Ksiazek, T.G. et al. (May 15, 2003). "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," <i>N. Engl. J. Med.</i> 348(20):1953-1966.	<i>Considered</i>
31.	Marshall, J.D. et al. (2003). "Novel Chimeric Immunomodulatory Compounds Containing Short CpG Oligodeoxynucleotides Have Differential Activities in Human Cells," <i>Nucleic Acids Research</i> 31(17):5122-5133.	<i>Considered</i>
32.	Merriam-Webster, Inc. (1983). <i>Webster's Ninth New Collegiate Dictionary</i> . Merriam-Webster, Inc.: Springfield, MA, pg. 57.	<i>Considered</i>
33.	Murakami, M. et al. (1999). "Human Papillomavirus Vaccines for Cervical Cancer," <i>J. Immunother.</i> 22(3):212-218.	<i>Considered</i>
34.	Pisani, P. et al. (1993). "Estimates of the Worldwide Mortality from Eighteen Major Cancers in 1985. Implications for Prevention and Projections of Future Burden," <i>Intl. J. Cancer</i> 55:891-903.	<i>Considered</i>
35.	Prince, G.A. (Summer 1994). "The Cotton Rat in Biomedical Research," <i>Animal Welfare Information Center Newsletter</i> 5(2), located at < <a href="http://www.nal.usda.gov/awic/newsletters/v5n2/5n2princ.html">http://www.nal.usda.gov/awic/newsletters/v5n2/5n2princ.html</a> >, last visited on February 16, 2006, six pages.	<i>Considered</i>
36.	Seo, S.H. et al. (September 2002). "Lethal H5N1 Influenza Viruses Escape Host Anti-viral Cytokine Responses," <i>Nature Medicine</i> 8(9):950-954.	<i>Considered</i>
37.	Smith, V.P. et al. (February 2002). "Inhibition of Interferons by Ectromelia Virus," <i>Journal of Virology</i> 76(3):1124-1134.	<i>Considered</i>
38.	United States Patent Application No. 09/802,518 filed on March 9, 2001 for Van Nest, 53 pages.	<i>Considered</i>
39.	Unknown. (Date Unknown). "Resiquimod (Topical), 3M," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...</a> >, last visited on October 7, 2005, 1 page.	<i>Considered</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature pa-1051641	<i>Emily Le</i>	Date Considered 6/05/06
----------------------------------	-----------------	----------------------------